Fireside: Paving the Path for Novel Radiopharmaceutical Targets or Following Bonified ADC Targets: Advantages & Pitfalls
Time: 1:30 pm
day: Conference Day One
Details:
- Leveraging established ADC Targets for radiopharmaceuticals for well characterized mechanism of action such as NECTIN-4
- Identifying and pursuing untapped biological targets to revolutionize radiopharmaceuticals such as failed ADC targets
- Commercial considerations to balance risks and hurdles
